Celgene Cp: (NASD: CELG)
$130.17
0.51 (0.39%)
Volume 3,787,553
May 14 04:00 PM ET
Zacks Rank: 2-Buy 
| #2 |
Overview Quote
Stock Activity
| Day Low - High | 129.33 - 131.82 |
| 52wk Low - High | 58.53 - 131.82 |
| Previous Close | 129.66 |
| Avg. Volume | 3,397,822 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 54.29 B |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.67 |
| PE (Forward) | 24.89 |
| Current Year Est. | 5.21 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
2 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
79 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | 24.89 |
| PEG Ratio | 1.02 |
| Current Year Est. | 5.21 |
| Current Quarter Estimate | 1.31 |
| Most Accurate Estimate | 1.31 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 07-25-2013 |
| EPS Last Year | 4.77 |
| Expected Earnings Growth | 24.49% |
Company Description
Celgene Corp. is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 1.31 | 1.29 | 5.21 | 6.36 |
| Number of Estimates | 4 | 4 | 4 | 4 |
| Low Estimate | 1.25 | 1.26 | 5.08 | 5.91 |
| High Estimate | 1.36 | 1.37 | 5.46 | NA |
| Year Ago EPS | 1.12 | 1.19 | 4.50 | 5.21 |
| EPS Growth | 16.74% | 8.61% | 15.78% | 22.12% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| CELGENE CORP | CELG | 129.66 | |
|
| AETERNA ZENTARS | AEZS | 1.87 | |
|
| ANIKA THERAPEUT | ANIK | 13.90 | |
|
| GENTIUM SPA-ADR | GENT | 8.31 | |
|
| NOVELOS THERAPT | NVLT | 0.44 | |
|
| AASTROM BIOSCI | ASTM | 0.60 | |
|
| ACHILLION PHARM | ACHN | 7.25 | |
|
| AFFYMAX INC | AFFY | 1.31 | |
|
| ALEXION PHARMA | ALXN | 104.86 | |
|
| ALKERMES INC | ALKS | 31.47 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Celgene Attains 52-Week High
May 14, 2013
NPS Pharma Incurs Narrower 1Q Loss
May 14, 2013
Setback for Endo Health on Opana ER
May 13, 2013
Genomic Gains Coverage for DCIS
May 13, 2013
Earnings Beat at Warner Chilcott
May 13, 2013
Positive Data on Celgene's Apremilast
May 09, 2013
Narrower Loss from Onyx, Guidance Maintained
May 08, 2013
The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie, Celgene and Telus
May 07, 2013
Financials
| EPS TTM | 4.77 |
| Sales | 5,507 |
| Net Income | 1,440 |
| Price/Earnings | 27.18 |
| Price/Book | 9.77 |
| Price/Cash Flow | 24.21 |
| Price/Sales | 9.53 |
News
3 Earnings Reports That Caught My Attention Last Week - TheMotleyFool
May 13, 2013
Buyers Accumulate Shares of Celgene, Up 2.5% - Financial News Network Online - Market Movers
May 13, 2013
Critical Alerts For Yahoo!, Celgene, Brinker International, Qlik Technologies, and Beam Released By InvestorsObserver - Pr Newswire
May 13, 2013
Shares of Celgene Rise Above Previous 52-Week High - Financial News Netwfork Online - 52-Week High-Lows
May 13, 2013
Stocks End Mixed In Quiet Trade; Stratasys Leads 3D Rally - Investors Business Daily
May 13, 2013
Top Trending on StockTwits (May 10) - Kapitall
May 13, 2013
Top-Rated Big-Cap Stocks Rising With Robust Market - Investors Business Daily
May 13, 2013
Actavis Joins Other Drugmakers On Elite IBD 50 - Investors Business Daily
May 11, 2013
Broker Recommendations
| Current ABR | 1.37 |
| ABR (Last Week) | 1.37 |
| # of recs in ABR | 26 |
| Average Target Price | 127.47 |
| Industry Rank by ABR | 79 out of 265 |
| Rank in Industry | 5 out of 155 |
